Compare AENT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AENT | NMRA |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.7M | 424.4M |
| IPO Year | N/A | 2023 |
| Metric | AENT | NMRA |
|---|---|---|
| Price | $7.26 | $2.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $10.00 | $8.00 |
| AVG Volume (30 Days) | 63.7K | ★ 970.4K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.70 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,088,441,000.00 | N/A |
| Revenue This Year | $7.29 | N/A |
| Revenue Next Year | $1.84 | N/A |
| P/E Ratio | $19.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.21 | $0.61 |
| 52 Week High | $11.57 | $11.57 |
| Indicator | AENT | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 39.73 |
| Support Level | $6.37 | $2.05 |
| Resistance Level | $8.45 | $2.36 |
| Average True Range (ATR) | 0.52 | 0.15 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 43.72 | 15.32 |
Alliance Entertainment Holding Corp is a distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world. The company has two divisions: Alliance Home Entertainment, which offers full-service support across production, marketing, and retail execution. and Alliance Authentic, which focuses on licensed collectibles and branded merchandise, including partnerships with Handmade by Robots, Master Replicas, and Weta Workshop.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.